Header

News archive

Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.

Showing 19 results

May 2024

Pulse UpdateMay 10, 2024
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML

April 2024

Pulse UpdateApr 09, 2024
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
Pulse UpdateApr 04, 2024
Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study

February 2024

Pulse UpdateFeb 16, 2024
Novartis appoints Sloan Simpson as Global Head of Investor Relations

January 2024

Pulse UpdateJan 08, 2024
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024

April 2023

Pulse UpdateApr 21, 2023
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®

March 2023

Pulse UpdateMar 02, 2023
Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch

January 2023

Pulse UpdateJan 09, 2023
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023

December 2021

Pulse UpdateDec 16, 2021
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease

September 2021